^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CDX-585

    i
    Other names: CDX-585, BSI-585, BSI 585, CDX 585, BSI585, CDX585
    Associations

    News

    Trials
    Company:
    Biosion, Celldex
    Drug class:
    PD1 inhibitor, ILT-4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study of CDX-585 in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=130, Recruiting, Celldex Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CDX-585
    over1year
    CDX-585, a novel bispecific antibody targeting PD-1 and ILT4 (AACR 2023)
    (2022 Clin Cancer Res 28: 57-70) reported encouraging results of the initial clinical study combining the ILT4 antagonist mAb MK-4830 with pembrolizumab. Doses of CDX-585 up to 60 mg/kg were well tolerated in cynomolgus macaques and displayed a favorable pharmacokinetic profile. Together these data demonstrate that CDX-585 effectively combines PD-1 and ILT4 blockade into one molecule with favorable biophysical and functional characteristics supporting the initiation of a dose-escalation clinical trial in patients with advanced solid tumors.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD40 (CD40 Molecule)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • CDX-585 • MK-4830